![](/img/cover-not-exists.png)
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis
Balak, Deepak M.W., van Doorn, Martijn B.A., Arbeit, Robert D., Rijneveld, Rianne, Klaassen, Erica, Sullivan, Tim, Brevard, Julie, Bing Thio, H., Prens, Errol P., Burggraaf, J. (Koos), Rissmann, RoberLanguage:
english
Journal:
Clinical Immunology
DOI:
10.1016/j.clim.2016.09.015
Date:
November, 2016
File:
PDF, 701 KB
english, 2016